InvestorsHub Logo

misiu143

03/06/18 2:20 PM

#20607 RE: tonecee #20605

Hi Tonecee- I believe that by know we all know treatment with Ibalizumab very well.

I dont believe that we are a treatment for the same patients , at least not at the beginning.

I am glad they are approved now .

I also believe that many of CCR5 patients will never go to this stage when they are on Pro 140.
And some CCR5 , when improved on IV treatment with Ibalizumab every 2 weeks , will at least try SC Pro 140 every week.

As always IMO only..


Inoviorulez

03/06/18 2:30 PM

#20608 RE: tonecee #20605

Doesn't matter.

With TaiMed's drug you have to receive it at a hospital or outpatient center intravenously. That wont' be good for commercial opportunity at all.

Secondly look at the side effects from the trial.

Yah no thanks Pro-140 remains better shape.

trding

03/06/18 2:49 PM

#20610 RE: tonecee #20605

Funny, in the comments everyone is talking about Pro 140 & CYDY. They had to halt THERF to slow it down, it jumped $2 on the news.

Grip it and Sip It

03/06/18 3:01 PM

#20613 RE: tonecee #20605

Only 43% success with horrible side effects, iv injection at a facility and must be combined with other treatments??? No thanks!

Based on this criteria, PRO-140 should be in doctors hands by Easter!

FDA is lacking in common sense sometimes!

Grip

Amatuer17

03/06/18 7:06 PM

#20624 RE: tonecee #20605

So where is pro-140 - still in trials - will not come to market for at least 15 months - even as combo